RRM2 and cancer: Recent studies also rendered RRM2 as a target in anti-cancer drug designation for treatment with anti-RRM2 drugs could reduce ribonucleotide reductase activity and consequently decreased the synthesis of dNTPs with concomitant inhibition of DNA replication, arrest of cells at S-phase, DNA damage, and finally apoptosis [42].